EUVIMEDEUVIMED entdecken
Crossref

Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis

Teppei Hagino iD, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Dermatitis® · 2025

DOI: 10.1089/derm.2024.0515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatitis®, 2025. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abstracts: Background: Some patients with moderate-to-severe atopic dermatitis (AD) show insufficient response to treatment with tralokinumab, an anti-interleukin-13 antibody. Identifying predictive factors for poor responders to tralokinumab can help optimize treatment strategies for AD patients.

Objective

To identify predictive factors for poor responders to tralokinumab, defined as an investigator’s global assessment >2 at week 12 or 24.

Methods

A prospective study was conducted from October 2023 to August 2024, including 109 Japanese patients with moderate-to-severe AD. Baseline features were compared between poor responders versus responders at week 12 or 24.

Results

Poor responders at week 12 showed higher baseline eczema area and severity index (EASI), lactate dehydrogenase (LDH), and eosinophil-to-lymphocyte ratio (ELR) compared with responders. Poor responders at week 24 had older age, longer disease duration, and higher proportions of previous systemic therapies, previous dupilumab, or previous 15 mg upadacitinib treatment, compared with responders.

Conclusions

Higher baseline EASI, LDH, and ELR may predict poor response to tralokinumab at week 12. Older age, longer disease duration, and previous usage of systemic therapy, dupilumab, or 15 mg upadacitinib may predict poor response to tralokinumab at week 24. AD patients with the above features may as well avoid tralokinumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, MonoclonalDermatologic AgentsHumansMaleFemaleAdultProspective StudiesSeverity of Illness IndexMiddle AgedTreatment OutcomeL-Lactate DehydrogenaseAntibodies, Monoclonal, Humanized

Substanzen

tralokinumabAntibodies, MonoclonalDermatologic AgentsL-Lactate DehydrogenasedupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino

Zitieren

APA

Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis. Dermatitis®. https://doi.org/10.1089/derm.2024.0515

Vancouver

Hagino T, Saeki H, Fujimoto E, Kanda N. Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis. Dermatitis®. 2025. doi:10.1089/derm.2024.0515

BibTeX
@article{Hagino2025,
  author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis},
  journal = {Dermatitis®},
  year = {2025},
  doi = {10.1089/derm.2024.0515}
}
Kostenlos starten →